ROCHE

Mabthera-reditux

"Mabthera" contains same Drug / Molecule called "Rituximab". Mabthera is produced through recombinant DNA technology. Mabthera is a monoclonal antibody against the protein found on the surface of immune system B cells. It induces cell death through antibody dependent cellular toxicity, complement dependent cytotoxicity, or apoptosis pathway.

“Reditux” is the generic version of “Mabthera” and both contains same drug “Rituximab”.

Details
Specification

Indication

Mabthera is used for certain types of cancer such as Lymphomas, Leukemia, Transplant Rejection and some autoimmune disorders. Mabthera may be used alone or in combination with other drugs for the treatment of Non-Hodgkin's Lymphoma and rheumatoid arthritis.

Note

Precaution

Mabthera is a prescription drug and should be used under proper medical guidance and advice.

Mabthera is not recommended if severe active infection is present.
May cause fatal renal toxicity in patients with hematologic malignancies.

Updated On Nov 01, 2019 by Admin

Strength

100 mg, 500 mg

Packing

Vial

Storage

Store under refrigeration between 2° to 8°C and protect from direct sunlight. Infusion solutions may be stored at 2°C to 8°C for 24 hours.

Was this page helpful?

☆ ☆ ☆ ☆ ☆

Not Upto Date Insufficient Helpful

Any suggestions or inputs for Shubhampharma.

Mabthera-reditux also available as

Dr. Reddys Laboratories Ltd

Reditux

REDITUX contains Drug / Molecule called “Rituximab”. Reditux is produced through recombinant DNA technology. Reditux is a monoclonal antibody against the protein found on the surface of immune system B cells. It induces cell death through antibody dependent cellular toxicity, complement dependent cytotoxicity, or apoptosis pathway.